In Entwicklung
Business·2.7.2026KI-Zusammenfassung
China's AI Drug-Design Firms Expand Globally Amid US Scrutiny
Chinese AI-driven drug-design firms are rapidly expanding their global presence through cross-border deals, with out-licensing agreements reaching US$75 billion in the first five months of 2026, despite increasing scrutiny from Washington on Chinese biotech companies. A deal between Metis TechBio and Boulevard Bio exemplifies this trend.
S
SCMP Economy1 Min. Lesezeit
